Treatment
Allopurinol clinical trials
We’re tracking 11 recruiting studies that include Allopurinol, each written for real people, not researchers, below.
Recruiting studies
- NCT07574060RecruitingPhase 2/Phase 3
Allopurinol as an Add-On Treatment for Depression
This trial tests whether allopurinol, a medication typically used for gout, might help reduce depression symptoms when added to standard depression treatment. Researchers believe it may work by reducing inflammation in the brain that contributes to depression.
TantaAges 18–60 - NCT07089888RecruitingPhase 3
Dotinurad vs allopurinol for gout with lumps
This trial is testing a new gout medication, dotinurad, compared to the standard treatment allopurinol for people with tophaceous gout (gout that causes hard lumps). It aims to see if dotinurad is better at reducing uric acid and shrinking those lumps.
Birmingham, AlabamaAges 18–75 - NCT07089875RecruitingPhase 3
Testing dotinurad vs allopurinol for people with gout
This study compares a new gout medicine called dotinurad to the common medicine allopurinol. It is for people who have had gout for at least a year, have had at least 2 gout attacks in the last year, and are already taking a stable dose of allopurinol but still have high uric acid levels.
Birmingham, AlabamaAges 18–75 - NCT04217421RecruitingPhase 3
Allopurinol for newborns needing heart surgery with bypass
This trial tests whether the medicine allopurinol can protect the brain and heart in newborns with serious congenital heart disease who need heart surgery soon after birth. It may help reduce injury during and around surgery that uses a heart-lung machine (cardiopulmonary bypass).
GroningenAges Up to 1 month - NCT05943821RecruitingPhase 3
Allopurinol to lower heart and stroke risks in high-risk people
This trial studies whether allopurinol can reduce the chance of cardiovascular events like heart attack, stroke, or related problems in people who are at higher risk. It targets people with higher uric acid and other risk factors, to see if lowering uric acid helps protect the heart.
Poznan, WielkopolskaAges 40–70 - NCT04026776RecruitingEarly Phase 1
Study hormones and salt sensitivity in adults born preterm
This early-phase study looks at natural body chemicals (uric acid and klotho) and how sensitive your blood pressure may be to salt. It may help researchers understand long-term health risks in people born very early.
Winston-Salem, North CarolinaAges 22–33 - NCT04875702RecruitingPhase 4
Compare urate targets to reduce gout attacks or symptoms
This study compares two different treatment goals for a blood level called urate in people with gout. The goal is to see which approach lowers gout flares better while helping people feel better.
South Birmingham, AlabamaAges 18–90 - NCT05536349RecruitingPhase 2
Testing three drug combo for untreated CLL or CLL-related cancer
This Phase 2 study tests pirtobrutinib plus venetoclax plus obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL) or CLL-related Richter transformation (RT). The goal is to see if this “triplet” combination works better and is safe enough to control the disease.
Houston, TexasAges 18 years+ - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Birmingham, AlabamaAges 18–39 - NCT07367971RecruitingPhase 1
ABP-671 interaction study for gout patients
This study tests how a new drug, ABP-671, interacts with allopurinol (a common gout medicine) in people with gout. It is looking for participants with normal or moderately reduced kidney function.
Cary, North CarolinaAges 18–75
What Allopurinol is being studied for
Conditions with recruiting Allopurinol studies.
Common questions
- Are there clinical trials studying Allopurinol?
- Yes. Clin2 currently lists 11 recruiting studies that include Allopurinol, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Allopurinol trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Allopurinol an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Allopurinol or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.